KNOWLEDGE BANK

Interviews

From Hallucinations to Evidence: LLMs clinicians can finally trust

Research Fellow, Institute of Health Informatics, University College London
Jinge Wu is a Research Fellow at the UCL Institute of Health Informatics specialising in multimodal large language models for clinical decision support and medical AI She has led research projects funded by UKRI MRC and Health Data Research UK working with largescale NHS electronic health record data to develop capable reliable and explainable AI for realworld clinical applications Her research ha...

Articles

Data-Enriched Edible Pharmaceuticals (DEEP) as Patient-Tailored Drug Products

Patienttailored treatment can be a challenge with conventional

Research Insights

Distribution Of Bacterial Contamination In Non-sterile Pharmaceutical Materials And Assessment Of Its Risk To The Health Of The Final Consumers Quantitatively

Abstract Bacterial contamination control in pharmaceutical products is a critical aspect in the field of drug manufacturing industry due to the encountered risk to the patients health and possibly their life The application of commercial bacterial identification system is crucial to identify the type of contamination and its source to anticipate the impac

Case Studies

High Concentration Antibody - Rituximab

Challenge Antibodies tend to aggregate at the high concentrations typically required for their therapeutic application The key challenge of this study was to reduce the rate of aggregation in isotonic aqueous formulation of rituximab at mgml whilst maintai

Techno Trends

Alkermes Introduces Alixorexton for the Treatment of Narcolepsy Type 1

Alkermes has introduced alixorexton for the treatment of narcolepsy type NT a chronic neurological disorder characterised by excessive daytime sleepiness and disrupted regulation of wakefulness

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

Unlocking New Avenues in Cancer Therapy by Targeting Ubiquitin-Specific Proteases

Dr. Oon Chern Ein

Associate Professor Dr. Oon Chern Ein is dedicated to advancing innovative cancer therapies. She earned her BSc (First Class Hons) in Biotechnology from Universiti Kebangsaan Malaysia and pursued her DPhil in Medical Oncology at the University of Oxford, United Kingdom. Following this, she trained as a postdoctoral fellow at Karolinska Institutet, Sweden. She has served as a lecturer at Universiti Sains Malaysia since 2013. Chern’s work in molecular therapeutics has earned her numerous prestigious awards, including the L’Oreal-UNESCO For Women in Science National Fellowship (2015), the Women of the Future Awards (South East Asia), and the Malaysian National Young Scientist Award (2018). She was further recognized with the Promising Academician Award and Excellent Service Award by the Malaysian Ministry of Higher Education (2019), alongside the British Council Study UK Alumni Award (Professional Achievement Category) and MINDS Women Scientist Award in 2020. Most recently, she received the Singapore Academies-ASEAN Fellowship from the Singapore National Research Foundation to train in drug discovery at A*STAR Singapore to strengthen her industrial insights. Her multidisciplinary research encompasses drug discovery, cancer-targeted therapies, and bioengineering solutions through collaborations with industry partners. She holds two granted patents in Malaysia (MY-203445-A, MY-199524-A) for small molecule inhibitors targeting anti-cancer and anti-angiogenesis pathways. As a member of the Global Young Academy, Chern actively champions female empowerment and education for all. Chern’s research continues to bridge academia and industry, striving to transform cancer therapy through novel therapeutic strategies.

2

Pharma Firms Must Come Together, Ensure Access to Antibiotics in Poor Countries to Take on Superbugs

Saransh Chaudhary

Entrusted with the mandate of augmenting and monetising the company’s intellectual property wealth and driving key tactical initiatives, Saransh Chaudhary joined Venus Remedies in 2016 as Strategic Board Advisor after completing his undergraduate degree in Accounting & Finance from Cass Business School, London. Two years later, he assumed charge as President of the company’s Global Critical Care division and CEO of Venus Medicine Research Centre (VMRC), its R&D wing. In these roles, he translates priorities into actionable strategies.

3

Evolution of eCTD from version 1 to 4

Gouspasha Mohammed

Gouspasha is a seasoned professional with 12 years of experience in the pharmaceutical industry, specializing in eCTD (Electronic Common Technical Document) publishing and submission. With a strong focus on regulatory compliance and efficient document management, Gouspasha ensures seamless and timely submissions. Dedicated to maintaining the highest standards of quality and accuracy, Gouspasha remains committed to staying current with evo0lving industry trends and regulatory requirements.

4

Synbiotics in Metabolic Health

Dr. Neeraj Mishra

Dr. Neeraj Mishra is working as Professor and Head, Department of Pharmaceutics,  in Amity Institute of Pharmacy, Gwalior since July 2019. He has around twenty years of teaching and research experience.  He has more than 100 publications of International and National repute in recent concepts of novel drug delivery systems, localised drug delivery, targeted and controlled drug delivery of nanocarriers/ microparticles for the treatment of breast, colon cancer, and neurodegenerative disorders. Dr. Mishra more than 3700 citations with h- index 32. The total cumulative Impact Factor of his published papers is more than 300 (as per SCOPUS). He has also written 15 Books and 30 book chapters in Elsevier, Bentham, Springer and Wiley Publication etc. He has also been granted 3 international patents and 2 Indian patents.  Dr. Mishra is recipient of “Distinguished Professor Award” 2019 from DST-NSTMIS, SPAICS, Indore, and M.P. in September 2019.  Dr. Mishra has received the “Distinguished Professor Award '' 2021 from Indian Pharmaceutical Association, MP State Branch, Indore.  Dr Mishra has received Best Academician Award in the Indian Pharmacy Graduate Association, M.P. State International Conference held on 06th May 2023 at DAVV Auditorium, Indore, India.

Devyani Rajput

Dr. Devyani Rajput is working as an Assistant Professor, Department of Pharmacognosy, in Amity Institute of Pharmacy, Gwalior since Jan 2024. She has around seven years of research experience. Her expertise includes nanotechnology, phytomedicine, and advanced drug delivery systems, with notable contributions to cancer research. She has participated in various national and international conferences, published impactful research, and received prestigious awards, including the BEST SCHOLAR AWARD 2023. She has more than 150 citations with h- index 3. She has received the CSIR travel Grant in April 2024 for presenting her research work in Istanbul University.

5

From Gene Editing to Network Medicine

Prof. Dr. Hemanth Kumar Manikyam

Prof. Dr. Hemanth Kumar Manikyam is a researcher in natural products chemistry and systems pharmacology. He is widely known as the father of Intrinsic Network Pharmacology (INP), an integrative framework combining artificial intelligence, biological network analysis, and traditional medicinal knowledge to explore complex therapeutic mechanisms and next-generation precision medicine.

press releasesRead more...

Waters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release

Waters Corporation announced that it has launched Waters AI Link a software capability that brings Anthropics Model Context Protocol MCP to its informatics platform and has joined Anthropics Model Hardware Standard MHS research program

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1

Takeda announced that ORZEYFUL oveporexton is now available in Japan and China for the treatment of narcolepsy type NT providing first access to clinicians to prescribe treatment with the new class of medicine ORZEYFUL is a firstinclass orexin receptor OXR agonist in tablet form designed to treat...

Merck Inaugurates State-of-the-Art ADVANCE Bioanalytical Facility on West Point, Pennsylvania, Campus

Merck known as MSD outside of the United States and Canada today inaugurated its stateoftheart ADVANCE research facility on its West Point Pennsylvania campus signaling a new chapter in global scientific discovery Pennsylvania Gov Josh Shapiro joined Merck executive leadership federal and state gove...

Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg

Alvotech a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited a global pharmaceutical company with a strategic focus on specialty hospital and rare disease medicines today announced the submissi...

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals Inc a global commercialstage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases today announced the commercial launch of IMCIVREE setmelanotide in Japan to treat patients living with acquired hypothalamic obesity HO...

Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement

Scinai Immunotherapeutics Ltd a biopharmaceutical company operating a growing contract development and manufacturing organization CDMO alongside an immunologyfocused therapeutic development platform today announced that its wholly owned subsidiary Scinai Biopharma Services Ltd has entered into a def...

EventsRead more...

21 - 23

Oct 2026

21 - 22

Oct 2026

22 - 23

Oct 2026

PDA Aseptic Symposium 2026

Congress Square Nakanoshima, O...

26 - 28

Oct 2026

ACHEMA Middle East 2026

RICEC, Riyadh, KSA, Saudi Arab...

26 - 28

Oct 2026

World Orphan Drug Congress

RAI, Amsterdam, Netherlands

27 - 28

Oct 2026

PM& AC 2026

Novotel Hyderabad Convention C...

28 - 30

Oct 2026

02 - 04

Nov 2026

Pharma Forum EMEA 2026

Dom Pedro Lisboa Hotel, Lisbon...

LATEST NEWSRead more...

Nxera Pharma Partners with Synmosa to Commercialise QUVIVIQ

Nxera Pharma has entered into an exclusive licensing supply and commercialisation agreement with Synmosa Biopharma to expand access to QUVIVIQ daridorexant a medicine used to treat insomnia across eight AsiaPacific markets QUVIVIQ was discovered and developed by Idorsia Pharmaceuticals

Vir Biotechnology Enters into Collaboration with Gilead Sciences to Develop T-cell Engagers for Solid Tumours

Vir Biotechnology has entered into a collaboration and licensing agreement with Gilead Sciences to discover and develop three novel Tcell engager TCE candidates for the treatment of solid tumours Tcell engagers are designed to direct T cells a type of immune cell towards cancer cells and help destro...

Zealand Pharma Enters into Collaboration with Generate Biomedicines on AI-Designed Protein Therapies for Metabolic Diseases

Zealand Pharma and Generate Biomedicines have entered into a multitarget collaboration and licensing agreement to develop proteinbased treatments for obesity and other metabolic diseases using artificial intelligence AI The collaboration will combine Zealand Pharmas expertise in metabolic diseases w...

Enodia Therapeutics Enters into Collaboration with Pfizer to Develop Small-Molecule Sec61 Inhibitors

Enodia Therapeutics has entered into a research collaboration and licensing agreement with Pfizer to discover and develop smallmolecule inhibitors targeting Sec a protein complex involved in the movement of newly formed proteins across cell membranes

InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China

InnoCare Pharma a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases announced today that the Center for Drug Evaluation CDE of Chinas National Medical Products Administration NMPA has approved its Investigational New Drug IND application for ICPB a bispeci...

Mint Pharmaceuticals and Bayer Expand Medicine Distribution in Canada

Mint Pharmaceuticals and Bayer have expanded their distribution partnership in Canada to include several additional medicines across womens health cardiovascular care and anticoagulation